Xenon Pharmaceuticals (XENE) Stifel 2025 Healthcare Conference summary

Key program updates

• Lead program azetukalner in epilepsy has fully enrolled phase III X-TOLE2, with data expected in early 2026.

• Azetukalner is also being studied in psychiatry, with two phase III trials in major depressive disorder and a new phase III trial in bipolar depression underway.

• Early-stage pain portfolio includes two phase I assets targeting NaV1.7 and Kv7, aiming for phase II proof of concept studies in 2026.

• Multiple catalysts expected: phase III readouts in epilepsy and psychiatry, and proof of concept data in pain.

Clinical trial insights and expectations

• Phase II-B data for azetukalner showed best-in-class efficacy in a severe epilepsy population, with rapid onset and strong safety profile.

• Phase III population closely matches phase II, with similar baseline characteristics and study sites.

• NDA filing planned for next year, with both X-TOLE and X-TOLE2 studies included in the package.

• Commercial launch preparations are underway, with leadership and field teams engaging the epilepsy community.

Commercial and market positioning

• Launch expected to be gradual due to the competitive landscape and availability of generics, but significant unmet need remains for focal onset seizures.

• Differentiation focuses on ease of use, safety, no titration, and novel mechanism, aiming to appeal to both specialists and general neurologists.

• Confident in ability to compete even as more branded drugs enter the market, citing high efficacy and unique mechanism.